Due to the decreased hepatic metastasis in two melanoma models and the increased premetastatic pro-inflammatory state in Lyve-1-KO, Lyve-1 might be an interesting therapeutic target [30] to further boost therapy response to ICI. This evidence concerns the gene LYVE1 and melanoma.